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1. Introduction  
The breast cancer rate is growing day by day 
and it will become the second most cause of 
mortality in women (1, 2). Amongst several 
types of cancer, breast cancer is the third most 
fatal cancer (3) in the United States and ap-
proximately 2.5 million peoples have breast 
cancers. This number will increase up to 4.2 
million in 2020 (4). Also, breast cancer is the 
most common cancer in the Asia.  Moreover, it 
has been in notice that the millions of the 
breast cancer were neither registered nor 
treated because of the lack of resources, poor 
registration system and lack of awareness 
during third-world countries (5). The 
symptoms of breast cancer which is closely 
associated with reaction to therapy, therapeutic 
evaluation and typical features of tissues (6), 
(7, 8). It has been observed that the breast 
cancer management and diagnosis 
improvement affect the mortality frequency 
and reduction on the mortality frequency 
depends on the various geographical locations 
(9, 10). The advance treatment in the early 
detection stages of the breast cancer can cure 
the cancer metastasis and such treatment can 
improve quality of life. Currently various 
treatments are available for the breast cancer 
such as radiation treatment, chemotherapy, 
endocrine treatment and surgery (11).  The 
development of Nano formulations such as 
liposomes (12) and nanoparticles (13), (14) of 
chemotherapeutic drugs are also trying to 
improve outcome of breast cancer therapy. 
After breast cancer treatment the monitoring of 
the patients is the key role because the adverse 
effect of the treatment or any reaction on the 
patients occurs but is it is depending on the 
cancer carcinoma. Institute of Medicine (IOM) 
collecting the data of the patients who has 
breast cancer to survivor in cancer and 
published comprehensive report in 2006. This 
milestone report is based on the regularly 
updated date and time of treatment summary, 
summary of diagnosis, healthy lifestyle 
recommendations, future follow up and plans 
(15). The another eloquently described special 
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series issue includes the brief summary of 
world-renowned experts advice and research 
data in meanwhile Institute of Medicine were 
published their research data (16). Also, it 
includes the treatment protocols, the 
development of lymphedema, bone health, the 
increased risk of second primary malignancies, 
long-term cardiovascular issues and other 
issues may not be life-threatening (16). 
 
Figure 1. National cancer Institute Breast cancer Research Portfolio (17). 
This issue focused on other multiple area such 
as the failure of adherence, risk of venous, 
hormonal therapies compliance and lifestyle 
changes. Non-specific symptoms such as   
insomnia, cognition fatigue etc. was not 
included because these symptoms are not 
specific and unique for the breast cancer (18). 
National cancer institute in the US funding in 
various essential sectors of breast cancer here 
in the figure 1 showing the 2013 fiscal year 
data. Survivorship care programs are playing 
significant role in the patient treatment 
pathway but somehow it fails in the 
communication and elaboration to patient 
regarding their long-term survival problems. 
For long term survival of the patients after 
treatment as per IOM 2006 data, continuous 
supervision and patient education to 
understand the problems play key role. In this 
article they have included and discussed the 
lymphedema, bone health, cardiovascular 
diseases, thromboembolic and second primary 
malignancy.  The breast cancer people are not 
died only because of the cancer disease but the 
other factors like diabetes mellitus, obesity, 
hyperlipidemia and hypertension are also 
affects the overall survival. The following 
sections of this review address the breast 
cancer therapy or treatment and its protocols 
long terms side effects and their protective 
approach for overall health. 
2. Treatment of the breast cancer according 
to carcinoma stages  
There are various stages of the cancer which 
includes association of lymph nodes, tumor 
size and existence of distant metastases. These 
stages are the reliable consistent prognostic 
signs of the breast cancer and depends on the 
cancer stages the therapy and treatment is 
started.  
In zero stage of the breast cancer lumpectomy 
alone can be applied in the infiltrating ductal 
carcinoma. However, in the larger lesions, 
lumpectomy is used with the radiation therapy.   
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Extensive Ductal Carcinoma in Situ involved 
two or more quadrants of the breast. It requires 
the mastectomy a surgical operation to remove 
a breast and Tamoxifen therapy is considered 
for all the breast cancerous patients (19, 20). 
As the standard protocol of the breast cancer 
treatment in stage I and stage II, radiation 
therapy and lumpectomy are applied on the 
patients to prevent the cancer after axillary 
lymph node status. Such treatments are 
effective in the breast cancer and have 
equivalent effects for lumpectomy and 
mastectomy. Therefore, the survival rate of the 
patients has been increasing up to 5 to 8 years 
with disease-free. The mastectomy should be 
recommended to former radiation therapy 
patients and eliminate the multi-centric disease 
and definite connective tissue diseases in 
breast cancer (21). In a breast cancer strategic 
and planned chemotherapy is used with 
radiotherapy. The chemotherapy treatments 
provided to the patients who have node 
positive breast cancer and Large tumors (22). 
Also, hormone receptor status has been 
evaluated for Adjuvant endocrine therapy 
treatment.  
The breast cancer with IIIa and IIIc stages is 
mostly treated by the resectable or may be non 
resectable (21). The resectable type can be 
treated by adjuvant chemotherapy with 
radiation therapy and modified radical 
mastectomy. Sometimes in several patient neo-
adjuvant chemotherapy is used to shrink the 
tumor size initially. Also, Adjuvant endocrine 
therapy is used in the inflammatory breast 
carcinoma and IIIb and IIIc cancer therefore 
the mukti treatment approaches are using to 
cure these stages of cancer. neo-adjuvant 
chemotherapy is used initially than if positive 
response of this treatment then modified 
mastectomy followed by radiation therapy may 
be employed (21). In some cases, 
chemotherapy should be advised to apply after 
these treatments. The figure 2 indicates the 
various stages of breast cancer. 
 
 
Figure 2. Breast cancer stages (17) 
The stage IV breast cancer is difficult to cure 
but some treatment like endocrine therapies are 
used to improve patient’s survival rates. 
estrogen receptor and progesterone receptor 
positive and negative in the breast cancer can 
be control by the asymptomatic visceral 
metastases and systemic chemotherapy 
respectively (23).  
3. Long term medical issues in breast cancer 
treatment 
As we have discussed in the above section 
breast cancer treatment has adverse effects on 
the patients. Here in this section discussed the 
cardiovascular diseases secondary to treatment. 
Moreover, it includes cardiac issues, 
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chemotherapy, Radiation Therapy, Hormonal 
Blockade, Targeted Biologic Therapies: 
Trastuzumab and Lapatinib and bone health 
3.1 Cardiac Issues in Breast cancer 
treatment. 
In the world it was observed that the feared 
disease causes the death in the women.  car-
diovascular diseases is one the most killer 
dieses in the women and approximately 400k 
women died in a year in united states. 
However, the breast cancer patient’s 
survivorship rate is increase because of the 
advance diagnostic system such as car-
diovascular diseases, effective treatment 
modalities and increased patient awareness 
(24). Also, these technological developments 
lead the mortality due to cardiovascular 
diseases. On the other hand, the breast cancer 
survivor’s death due to cardiovascular diseases 
has been observed at the time of diagnosis, 
regardless of cancer stage and adjuvant 
therapies. 
Furthermore, cardiovascular diseases and the 
breast cancer diagnosis in the young women at 
the age of 30 to 40 increases which need more 
attentions. The modern protocol is used to 
procured the breast cancer. Also, the others 
treatments are applied on the patient to cure 
the other side effects. It has been observed that 
the subspecialty cardio-oncology-a specialty is 
managing the cardiovascular effects of the 
treatment of malignancies (25). As per the 
research information many breast cancer 
survivors have a risk of cardiovascular 
diseases and number of death causes because 
of cardiovascular diseases in Breast cancer.  
3.2 Chemotherapy and Radiation Therapy for 
breast cancer  
The multiple antineoplastic agents are used as 
breast cancer treatment and increased overall 
survivor of the patient. Unfortunately, in 
chemotherapeutic the used many drug agents 
cause the cardiovascular and some of them are 
most chronic (26). The breast cancer treatment 
causes the cardiovascular decease such as 
hypertension, bradycardia acute coronary 
syndrome and congestive heart failure (27). In 
breast cancer chemotherapeutic treatment 
cardiotoxicity of systemic therapies are one of 
the major affecting components for 
cardiovascular decease. Also, such devastating 
consequences of treatment majorly affects 
when smoking, hypertension and history of 
coronary artery disease were listed in the 
patient history. Table 1 indicates the long-term 
effects of conjunctive therapies for breast 
cancer. 
Table 1. Potential cardiotoxicity of therapeutic agents 
Chemotherapeutic Agent Potential cardiotoxicity 
Taxanes: paclitaxel and docetaxel  Ischemia, arrhythmias and congestive heart 
failure  
Targeted therapies: trastuzumab and lapatinib  congestive heart failure   
Hormonal blockade: tamoxifen  thromboembolic events 
Anthracyclines: doxorubicin and epirubicin  cardiomyopathy and congestive heart failure   
Alkylating agents: cyclophosphamide  congestive heart failure 
 
In the breast cancer at the early stage surgical 
options are given to the patient to cure the 
cancer.  In 1970s the breast-conserving therapy 
has been effectively started with 
quadrantectomy vs mastectomy. After the 
numerous studies it has been fully verified that 
the breast-conserving therapy is the first 
primary surgical option for treatment (28).   
The radiation therapy is an adjuvant part of 
breast-conserving therapy (29). The use of 
radiation therapy in treatment causes the 
Cardiac injury. Such therapy damages the 
coronary arteries and myocardium therefor 
increases the congestive heart failure risk.  
Henceforth, the chemotherapy and radiation 
therapy cause the risk of cardiac attack but it 
can be start after the 10 years of treatment 
(30).  
3.3 Hormonal Blockade, Targeted Biologic 
Therapies: Trastuzumab and Lapatinib and 
Bone Health 
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The growth of the breast cancer cell can be 
preventing by the Tamoxifen which is 
selective estrogen receptor modulator. In 
Tamoxifen antiestrogenic activity through its 
competitive inhibition of estrogen binding to 
estrogen receptors (31).  Tamoxifen is the most 
effective as breast cancer treatment and 
reduced the risk of mortality. Such treatment is 
more significant because of most of the 
patients have estrogen receptor-positive 
cancer. On the other side Tamoxifen has side 
effects like menopause, mood swings, vaginal 
dryness, mood swings and hot flashes. In 
addition to this tamoxifen increases risk of   
cerebral vascular events, pulmonary embolism, 
thromboembolic complications and develop 
endometrial cancer. Therefore, women are 
affected with the hormonal blockade and many 
other issues. Tamoxifen is increasing the 
cardiovascular decease risk and myocardial 
infarction (20). 
The Targeted biologic agents are directed at 
protein kinases and the receptors that activate 
them Almost 30% of the breast cancers are 
human epidermal growth factor receptor 2-
positive (32) and its tyrosine kinase pathway 
has been used as significant therapeutic target 
(33), (34) Several targeting ligands such as 
peptides and antibodies are used to target 
specific type of cancer cells (35) Trastuzumab 
therapy is extended the life span of the patients 
but its adversely affect to the cardiac function. 
However, its cardiotoxicity mechanism is still 
uncleared (36). Therefore, cardiovascular 
decease risk is increases. 
In the breast cancer an osteoporosis and bone 
loss developed because of the adjuvant 
therapies. However, to maintain the bone 
integrity in the breast cancer is a challenging 
issue. mostly osteoporosis has been seen in to 
elderly population in breast cancer and can be 
recognize by modifiable and non-modifiable. 
Recently many gene therapy approaches are 
also coming up and in clinical trials for 
treatment of various types of cancers such as 
colorectal cancer (37) (38) lung cancer, and 
breast cancer. Thus, a lot of research is going 
on to Improve the cancer therapeutic 
alternatives for breast cancer and reduce 
associated side effects at the same time (39). 
4. Conclusion 
To decrease augment survival rate and 
recurrence rate, adjuvant therapy is most 
effective for all patients of breast cancer. 
Aromatase Inhibitors are used for breast cancer 
in women because of hormone receptor 
positive and effective than Tamoxifen. Women 
have negative hormone receptor in breast 
cancer and Chemotherapy treatment is given to 
premenopausal women. Anthracycline 
treatment as chemotherapeutic agents are 
efficient and proven treatment for breast 
cancer but it is particularly high risk for 
patients. 
Form the last decade the survivorship in the 
breast cancer is the challenging issue. 
However, early diagnosis can lead the survivor 
rate of breast cancer patients. The new 
challenge in the medical sectors about the 
breast cancer is long term complications of 
current and past treatment. Current therapy 
such as radiation therapy, polychemo-
therapeutic agents can affect the cardiovascular 
system. The Cardiovascular disease is the most 
common mortality in breast cancer women. 
The breast cancer treatment such as 
chemotherapy, Radiation Therapy, Hormonal 
Blockade, Targeted Biologic Therapies: 
Trastuzumab and Lapatinib and bone health 
have may side effects and based on the various 
medical patient data it is proven that the long-
term side effects cannot be cured such as 
cardiac issues. On the other side to treat and 
cure the cancer at various stages patients has to 
take the treatment to survive the life. Although 
the new generation and development of the 
technology may reduce the mortality rate and 
improve the survivorship in breast cancer.  
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